Acadia Pharmaceuticals ACAD Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.64M-80.8% | $273.57M+90.3% | $71.78M+119% | $26.67M-20.1% | $18.99M+14.7% | ||
| $271K+18.3% | $202K-10.6% | $227K+0.4% | $213K-5.8% | $229K-5.4% | ||
| $14.7M+29.2% | $13.24M+26.7% | $13.18M-49.6% | $14.34M-8.6% | $11.38M-22.8% | ||
| -$94K— | —— | —— | —— | $0— | ||
| $13.89M+98.4% | $5.61M+958% | $8.35M+252% | $1.76M-80.4% | $7M+296% | ||
| -$78K-101% | $4.89M+10.6% | $0-100% | $4.1M-84.9% | $10.45M-37.2% | ||
| $1.34M-29.4% | -$10.84M-275% | $1.65M+306% | $2M+264% | $1.9M+6.4% | ||
| $23.56M+20,408% | -$68.39M-322% | $27.78M+110% | $21.47M+44.6% | -$116K-101% | ||
| $32K-94.5% | $1.84M-89.0% | $700K+698% | $721K— | $585K— | ||
| -$6.5M-441% | $5.25M+92.0% | -$14.66M-595% | $8.59M+688% | $1.91M+149% | ||
| $5.07M+270% | —— | $8.12M+47.8% | —— | -$2.98M-181% | ||
| $2.72M0.0% | $2.72M-45.4% | $2.72M+16.2% | $2.72M+16.1% | $2.72M-48.5% | ||
| -$13.74M-782% | $3.19M— | $11.4M+109% | $4.21M+220% | $2.02M+55.6% | ||
| $33.98M+67.2% | —— | $74.29M+17.5% | $63.96M+156% | $20.32M-30.1% | ||
| $5.21M— | $4.01M+784% | $388K+454% | $297K— | $0— | ||
| $15.01M-90.4% | $157.61M+16.1% | $204.55M+35.0% | $174.39M+26.7% | $156.01M+94.6% | ||
| $86.5M-33.9% | $105.75M-5.5% | $125.59M+81.7% | $131.39M+61.2% | $130.8M+97.8% | ||
| $0-100% | —— | —— | —— | $98.84M— | ||
| $66.28M+153% | -$55.87M— | -$79.35M+3.8% | -$43.29M+23.0% | -$124.05M-784% | ||
| $4.23M+130% | $22.67M+1,051% | $9.42M+3,416% | $15.96M+348% | $1.84M+76.2% | ||
| $4.23M+130% | $22.67M+1,051% | $9.42M+3,416% | $15.96M+348% | $1.84M+76.2% | ||
| $25K+600% | $7K+112% | $0+100% | $24K+700% | -$5K-200% | ||
| $104.52M+203% | -$81.93M-150% | —— | —— | -$101.89M-733% | ||
| —— | $6.29M+28.9% | $6.29M+28.9% | $6.29M+28.9% | $6.29M+28.9% | ||
| $453K-78.6% | $670K-76.2% | $1.1M-59.9% | $1.54M-21.4% | $2.12M+18.5% | ||
| $2.72M0.0% | $2.72M-45.4% | $2.72M+16.2% | $2.72M+16.1% | $2.72M-48.5% | ||
| $271K+18.3% | $202K-10.6% | $227K+0.4% | $213K-5.8% | $229K-5.4% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$13.74M-782% | $3.19M— | $11.4M+109% | $4.21M+220% | $2.02M+55.6% | ||
| -$2.16M-1.3% | -$2.2M+7.7% | -$2.21M-50.0% | -$2.12M-12.3% | -$2.14M-21.5% | ||
| -$2.18M-692% | -$2.92M— | -$2.18M+61.8% | -$1.79M+22.3% | $369K+74.1% | ||
| $32K-94.5% | $850K— | $700K+698% | $721K— | $585K— | ||
| $5.07M+270% | —— | $8.12M+47.8% | —— | -$2.98M-181% | ||
| $0-100% | —— | —— | —— | $98.84M— | ||
| $86.5M-33.9% | $105.75M-5.5% | $125.59M+81.7% | $131.39M+61.2% | $130.8M+97.8% | ||
| $879K+15.8% | $356K-29.9% | —— | $3.28M— | $759K-91.9% | ||
| $25K+600% | $7K+112% | $0+100% | $24K+700% | -$5K-200% | ||
| —— | $0-100% | $0— | $0— | $0-100% | ||
| $2.2M— | —— | —— | —— | $0— | ||
| $118K+25.5% | $193K+972% | —— | $214K— | $94K-51.5% | ||
| —— | $6.29M+28.9% | $6.29M+28.9% | $6.29M+28.9% | $6.29M+28.9% | ||
| $28.77M+41.6% | —— | $73.9M+17.0% | $63.66M— | $20.32M— | ||
| $28.77M+41.6% | —— | $73.9M+17.0% | $63.66M— | $20.32M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Acadia Pharmaceuticals generate?
- Acadia Pharmaceuticals (ACAD) generated $192.5M in operating cash flow over the trailing twelve months.
- What is Acadia Pharmaceuticals's free cash flow?
- After $9.9M of capital expenditures, Acadia Pharmaceuticals's free cash flow was $186.7M over the trailing twelve months, up 13.4% year over year.
- Where does Acadia Pharmaceuticals's cash flow data come from?
- Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
